BISANTRENE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII 39C34M111K

Structure

InChI Key NJSMWLQOCQIOPE-OCHFTUDZSA-N
Smiles C(=N/NC1=NCCN1)\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12
InChI
InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H22N8
Molecular Weight 398.47
AlogP 1.76
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 4.0
Polar Surface Area 97.56
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor INHIBITOR PubMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Oxidoreductase
- 25000 - - -
Assay Description Organism Bioactivity Reference
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL Homo sapiens 0.0 %
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL Homo sapiens 33.3 %
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) Homo sapiens 97.7 %
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) Homo sapiens 79.9 %
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL Homo sapiens 0.0 %
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL Homo sapiens 21.0 %
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) Homo sapiens 92.9 %
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) Homo sapiens 91.6 %
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL Homo sapiens 0.0 %
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL Homo sapiens 20.2 %
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill) Homo sapiens 63.5 %
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill) Homo sapiens 41.9 %
Compound was tested for potency against human lung A549 cells using sulforhodamine B assay. Homo sapiens 17.0 nM
Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line Homo sapiens 340.0 nM
Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line Homo sapiens 300.0 nM
Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL Mus musculus 1.8 %
Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL Mus musculus 9.3 %
Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) Mus musculus 66.8 %
Effect on DNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) Mus musculus 43.6 %
Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL Mus musculus 0.0 %
Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL Mus musculus 24.1 %
Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) Mus musculus 96.1 %
Effect on RNA synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) Mus musculus 21.7 %
Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.01 ug/mL Mus musculus 0.0 %
Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 0.1 ug/mL Mus musculus 5.6 %
Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 10 ug/mL (*: >1 log cell kill) Mus musculus 89.0 %
Effect on protein synthesis was determined by incorporation of radioligand into L1210 murine leukemia at a concentration of 1 ug/mL. (*: >50% cell kill) Mus musculus 48.5 %
Compound was tested for potency against multidrug-resistant murine leukemia L1210 cells Mus musculus 49.0 nM
Percent tumor inhibition at non-lethal dose was determined in BDF1 mice with madison lung 109 leukemia; 1, 5, 9 days of sc treatment relative to tumor inoculation Mus musculus 20.0 %
Compound was tested for potency against human myeloma 8226 cells using MTT assay method. Homo sapiens 18.0 nM
Compound was tested for potency against human colon carcinoma SW 480 cells in a sulforhodamine B assay. Homo sapiens 90.0 nM
Compound was tested for potency against human colon carcinoma WiDr cells in a sulforhodamine B assay. Homo sapiens 790.0 nM

Cross References

Resources Reference
ChEMBL CHEMBL25336
DrugCentral 376
FDA SRS 39C34M111K
PubChem 5351322
SureChEMBL SCHEMBL7207049
ZINC ZINC000001577736
CONTENTS